BIIB

Biogen Inc. (BIIB) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Biogen Inc. is a global biopharmaceutical company focused on neurology, specialized immunology, and rare diseases. The company operates as a single segment and continues to navigate a competitive landscape marked by generic and biosimilar erosion of its Multiple Sclerosis (MS) portfolio, while driving growth through new product launches (SKYCLARYS, QALSODY, ZURZUVAE) and strategic collaborations (LEQEMBI).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 1.9% year-over-year. Product revenue grew 1.5% to $1,752.3 million.
  • MS Portfolio: Revenue was flat (+0.5%) at $957.5 million. Significant growth in TYSABRI (+15.7%) and VUMERITY (+29.0%) was offset by a 46.9% decline in TECFIDERA due to generic competition.
  • Rare Disease: Revenue declined 1.1% to $557.2 million, driven by unfavorable inventory dynamics for SPINRAZA, partially offset by growth in SKYCLARYS (+21.6%) and QALSODY (+109.7%).
  • Collaborations: Alzheimer's collaboration revenue (LEQEMBI) surged 80.3% to $59.5 million. Anti-CD20 program revenue increased 10.8% to $419.1 million.
• Profitability: Net income rose significantly, driven by a 83.1% reduction in "Acquired in-process research and development, upfront and milestone expense" ($34.0M vs. $200.7M in Q1 2025) and a lower effective tax rate.
• Expenses: R&D expense increased 24.2% to $539.0 million, primarily due to SKYCLARYS inventory step-up amortization ($56.8M) and higher clinical trial spend. SG&A increased 6.1% due to product launch activities.

Guidance, Outlook, and Risks

• Strategic Acquisitions: In March 2026, Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion (cash + contingent value rights) to add SYFOVRE and EMPAVELI to its portfolio. Funding will utilize ~$3.6B cash and ~$2.0B in bank loans. In April 2026, Biogen acquired exclusive worldwide rights to felzartamab from TJ Bio for a $100M upfront payment.
• Product Outlook: Management expects MS revenue to decline in 2026 due to generic competition. Rare disease revenue is expected to grow driven by SKYCLARYS and QALSODY launches. ZURZUVAE revenue is anticipated to grow with increasing patient volume.
• Regulatory & Pricing Risks:
  • IRA Impact: The Inflation Reduction Act's Medicare Part D redesign had a modest net unfavorable impact of ~$90M on full-year 2025 revenue.
  • OBBBA: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 introduces tax changes and Medicaid funding modifications; full impact remains uncertain.
  • Tariffs: New U.S. tariffs on pharmaceutical imports (effective Sept 2026) and geopolitical tensions create supply chain and cost uncertainties.
• Legal Proceedings: Ongoing litigation includes securities actions, antitrust claims regarding PBM contracts, and patent disputes (e.g., IMRALDI, TECFIDERA). A judgment of ~$124.3M was entered against Biogen in a Genentech royalty dispute in Nov 2025; Biogen has appealed.

Investor Verification Checklist

• Apellis Acquisition: Verify the closing timeline, regulatory approvals, and integration plans for the $5.6B Apellis deal.
• TECFIDERA Decline: Monitor the rate of revenue erosion in the MS portfolio as generic competition expands in the E.U. and U.S.
• LEQEMBI Commercialization: Track sales velocity and reimbursement status for LEQEMBI, particularly the subcutaneous autoinjector (IQLIK) approval expected in May 2026.
• Tariff Exposure: Assess the potential financial impact of the 100% tariff on patented pharmaceutical imports effective September 29, 2026, given Biogen's global manufacturing footprint.
• Legal Reserves: Review the status of the Genentech royalty appeal and the potential liability from antitrust and securities litigation.